PepGen Inc

PepGen Inc operates with a strong liquidity position, as evidenced by a current ratio of 7.45 and cash and equivalents of $66.09 million, which significantly exceeds its total liabilities of $38.47 million. The company's price-to-book ratio of 0.74 indicates that its market value is trading below its book value, suggesting potential undervaluation. However, the company's liquidity is not supported by positive operating cash flow, which was negative at -$38.89 million in the latest period.

Profitability metrics for PepGen are negative, with a net income of -$28.34 million and an operating income of -$30.43 million. The company's return on equity (ROE) is -18.28%, and its return on assets (ROA) is -14.64%, both of which are significantly below the industry median for biotechnology firms. These figures indicate that the company is not generating returns for shareholders and is underperforming in asset utilization.

PepGen's revenue is not disclosed in the provided data, and no specific geographic or segment breakdown is available. However, the absence of long-term debt and the low dilution risk suggest that the company is not heavily reliant on external financing or equity issuance to fund operations. This may indicate a more stable capital structure, but it also suggests limited growth through debt or equity financing.

Looking ahead, the company's growth trajectory is uncertain. The latest financial data shows a negative free cash flow of -$27.97 million and a capital expenditure of -$84,000, indicating that the company is not investing in new projects or expanding its operations. Analysts have provided a wide range of price targets, from $3.00 to $20.00, with a mean of $10.14 and a median of $10.00, suggesting a high degree of uncertainty about the company's future performance.

The risk assessment for PepGen indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the company's negative operating and net income, along with its negative cash flows, suggest that it is not currently generating sustainable earnings. The absence of long-term debt and the low dilution risk may provide some stability, but the company's financial performance remains a concern.

Recent events and filings do not provide specific details about the company's operations or strategic direction. The lack of disclosed revenue segments and geographic exposure makes it difficult to assess the company's market position and diversification. The company's reliance on cash and equivalents to fund operations may limit its ability to invest in growth opportunities or respond to market changes.

Operating income +39,5% YoY; Net income +41,2% YoY.

• ▍Operating income +39,5% YoY
• ▍Net income +41,2% YoY
• ▍Free cash flow +41,7% YoY

Operating income +19,1% YoY; Net income +17,5% YoY.

• ▍Operating income +19,1% YoY
• ▍Net income +17,5% YoY
• ▍Free cash flow +18,4% YoY

Operating income +19,5% YoY; Net income +15,7% YoY.

• ▍Operating income +19,5% YoY
• ▍Net income +15,7% YoY
• ▍Free cash flow +16,0% YoY

Operating income +21,3% YoY; Net income +18,5% YoY.

• ▍Operating income +21,3% YoY
• ▍Net income +18,5% YoY
• ▍Free cash flow +18,5% YoY

Operating income -$31.3M.

• ▍Operating income -$31.3M

Operating income -$24.3M.

• ▍Operating income -$24.3M

Operating income -$23.2M.

• ▍Operating income -$23.2M

Operating income -$30.4M.

• ▍Operating income -$30.4M

Operating income +4,2% YoY; Net income +0,4% YoY.

• ▍Operating income +4,2% YoY
• ▍Net income +0,4% YoY
• ▍Free cash flow +0,5% YoY

Operating income −15,3% YoY; Net income −14,4% YoY.

• ▍Operating income −15,3% YoY
• ▍Net income −14,4% YoY
• ▍Free cash flow −11,2% YoY

Operating income −24,1% YoY; Net income −13,8% YoY.

• ▍Operating income −24,1% YoY
• ▍Net income −13,8% YoY
• ▍Free cash flow −10,6% YoY

Operating income −151,9% YoY; Net income −153,3% YoY.

• ▍Operating income −151,9% YoY
• ▍Net income −153,3% YoY
• ▍Free cash flow −162,3% YoY